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In recent years, the use of lytic bacteriophages as antimicrobial agents controlling
pathogenic bacteria has appeared as a promising new alternative strategy in the face of
growing antibiotic resistancewhich has caused problems inmany ﬁelds includingmedicine,
veterinarymedicine, and aquaculture.The use of bacteriophages has numerous advantages
over traditional antimicrobials. The effectiveness of phage applications in ﬁghting against
pathogenic bacteria depends on several factors such as the bacteriophages/target bacteria
ratio, the mode and moment of treatment, environmental conditions (pH, temperature...),
the neutralization of phage and accessibility to target bacteria, amongst others. This
report presents these factors and the challenges involved in developing phage therapy
applications.
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INTRODUCTION
Bacteriophages (phages) are viruses that only infect bacteria. They
are approximately 50 times smaller than bacteria (20–200 nm)
and ubiquitous in the soil, water, and several food products (meat,
vegetables, dairy products...; Kutter and Sulakvelidze, 2005). The
“virulent” and “temperate” phages differ in their mode of action.
The ﬁrst step of the phage infection is adsorption of the phage par-
ticle to the bacterial cell wall by speciﬁc interactions between viral
surface proteins and host cell receptors. After entering the bacterial
cell, the virulent phages replicate rapidly to synthesize genome and
structural proteins into progeny virions inside the host cell. Finally
the new phages escape by rupturing the cell wall which results in
the death of the cell. In contrast, temperate phages integrate their
genetic material into the chromosome of the host cell, which is
replicated along with the host cell genome (prophage). They can,
therefore, subsequently emerge inside a new host cell. Only tem-
perate phages which can enter the bacterial genome participate
in horizontal gene transfers between bacterial populations. For
antibacterial applications, virulent phages which have the ability
to rapidly lyse bacterial cells are employed.
The use of bacteriophages to treat bacterial infections was stud-
ied prior to the SecondWorldWar. These studieswere not followed
up once antibiotics had been discovered. But in recent years, with
the emergence of several bacterial strains multiresistant to antibi-
otics, research has turned back to bacteriophages. The use of
phages to inactivate pathogenic bacteria is seen as an interesting
way of replacing antibiotics in human medicine. Indeed, bacte-
riophages are considered as “intelligent antimicrobials” due to the
speciﬁcity of their action. They infect the target bacteria without
any effect on commensal ﬂora and are naturally eliminated along
with the complete eradication of pathogenic bacteria (Kutateladze
and Adamia, 2010; Jenny, 2011).
In veterinarymedicine, numerous studies have been carried out
to combat bacterial diseases and control transmission to humans
of the pathogens responsible for foodborne illnesses. For exam-
ple, the reduction of Campylobacter and other pathogenic bacteria
contamination by phages has been studied in several publications
(Berchieri et al., 1991; Goode et al., 2003; Connerton et al., 2004;
Fiorentin et al., 2005; Wagenaar et al., 2005; Higgins et al., 2008).
The poultry and medical ﬁelds can beneﬁt from these results,
in terms of reducing economic losses and improving the overall
well-being of consumers.
Bacteriophages have been studied in the agri-food industry
in order to detect and control pathogenic bacteria in foodstuffs
(Martínez et al., 2008; Guenther et al., 2009; Holck and Berg, 2009;
Jamalludeen et al., 2009; Kocharunchitt et al., 2009; Hudson et al.,
2010; Bigot et al., 2011; Mahony et al., 2011). The advantage of
using lytic phages lies in their high speciﬁcity toward the host
pathogenic bacterial strains. They do not affect technological ﬂora
or the commensal ﬂora of the digestive tract. In addition, bacterio-
phages do not cause human allergies and nor do they change the
structure, odor or ﬂavor of food products (Hagens and Offerhaus,
2008).
Research on the phages has been extensive over the last decade
(Pirnay et al., 2012). Many animal models have been available for
reliable studies. Research on phages has expanded beyond the lab-
oratory. Phage products have been approved and commercialized.
Regularly, approvals have been granted in the USA for commercial
phage products. In 2006 the FDA (Food andDrugAdministration)
approved the use and the preparation of bacteriophages generally
recognized as safe (GRAS) as food additives for the control of
the pathogenic bacterium L. monocytogenes in meat and poultry
products. In Europe, the use of ListexTM was also approved in
Switzerland for cheese making and has recently been approved for
other food types. The ListexTM has also been approved for use
in food processing by food standards Australia and New Zealand
(FSANZ) in 2012. Several phage products are currently produced
on a commercial scale:
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BACTERIOPHAGES ON A COMMERCIAL SCALE
LMP-102TM (ListshieldTM) produced by Intralytix Inc. (USA)
includes six bacteriophages This product occurs naturally in the
environment and is used to control L. monocytogenes in ready-
to-eat meat and poultry products before packaging. Other similar
products such as ECP-100TM (EcoshieldTM) target E. coli O157:H7
in ground beef, fruits, and vegetables.
ListexTM is a phage preparation derived from phage P100 that
targets L. monocytogenes by EBI Food Safety (Netherlands). Phage
P100 was originally isolated from a wastewater sample taken from
a dairy plant in Germany in 1997 (Carlton et al., 2005). In 2011
the company started selling its newphage product, effective against
Salmonella, branded: SALMONELEXTM.
Omnilytics, Inc. (USA) has two products that target bacte-
ria on animal hides prior to slaughter. Both products are termed
BacWashTM targeting Salmonella andE. coliO157:H7. BacWashTM
can be applied as a wash, mist or spray directly to the live animal.
Future potential uses of the BacWashTM line of products include
the treatment of animal holding areas, transportation equipment
and containers, and living areas.
Other phage products are currently commercialized and devel-
oped by several companies such as AgriPhage TM of Omnilyics
(USA) targets Xanthomonas campestris or Pseudomonas syringae.
BioPhage-PA is product of AmpliPhi biosciences Corp (UK) for
the treatment against Pseudomonas aeruginosa in chronic ear dis-
ease and topical injection. Viridax TM is being developed to treat
the S. aureus by Viridax Company (USA).
Despite this increase in research interest and the produc-
tion of phage products, the application in phage therapy was
not always successful. The effectiveness of phage applications
against pathogenic bacteria depends on several factors such as the
bacteriophage/bacteria ratio, physico-chemical factors (pH, tem-
perature...), phage neutralization or resistance to phage. Moreover,
the data in vitro cannot be directly applied to the in vivo situation
and nor can in vivo data for one phage be transferred to another
phage. Critical parameters that affect phage therapy are the phage
adsorption rate, burst size, the latent period and initial phage
dose (Payne et al., 2000; Payne and Jansen, 2001). Another critical
parameter is the clearance rate of the phage particles from the body
ﬂuids by the reticuloendothelial system or the phage-neutralizing
antibody phenomena. Some key factors are presented in Figure 1.
Phages/bacteria ratio
The use of bacteriophages against pathogenic bacteria has been
studied using two different approaches, one passive, the other
active (Gill, 2010). In the case of the passive approach, the bacte-
riophages are added into the system at a level sufﬁcient to ensure
that all target bacteria are infected and lysed in a short period
of time. On the contrary, active biocontrol relies on the addition
of a small amount of phages. Bacterial elimination, in this case,
supposes the replication of phages over several generations. The
capacity of new replicated phages to access the target bacteria could
be weakened by the biochemical and physico-chemical character-
istics of the system (the viscosity for example). It appears that the
passive treatment is more efﬁcient than the active one.
In virology the bacteriophages/bacteria ratio is explained by the
term MOI (multiplicity of infection) which refers to the number
of virus that are added per cell during infection. MOI is used only
in ﬂuid systems with high numbers of host cells. In in vitro and in
vivo experiments on phage against bacteria, the MOI comprised
between 0.01 and 100 are classically used. Most often, MOI is 100
to ensure there is enough phage in the media. However, not all
phages replicate or survive in the same way. It is important to
determine the replication lytic cycles and the resistance of phages
in respect of environmental conditions.
Environmental conditions and phage resistance
The survival and persistence of bacteriophages are affected by
physico-chemical factors (pH, ions, temperature...; Jonczyk et al.,
2011). The phage population is generally stable in relation to
external factors. Some phages can be stored for a long period
in neutral pH (6 to 8) in solution or in dried form (Jonczyk
et al., 2011). Phage titers generally are decreased slowly with
pH. For example, the phage titer of S. aureus was reduced 2
log between 4 and 6 h when pH decreased from 6.19 to 5.38
(Garcia et al., 2009). The proliferation of several phages is limited
when pH is lower than 4.5, but the risk of pathogenic bacte-
ria food contamination is also generally reduced below pH 4.5.
For example, the phage T4 (Myoviridae family) is unstable at
pH< 5. Phage PM2 (Corticoviridae family) loses completly activ-
ity after 1 h at pH 5.0 at 37◦C. However, in the case of phage
oral injection, stomach acid can have a negative impact on the
survival of phage which may lead to treatment failure (Watan-
abe et al., 2007). The latent period is increased when the phages
are incubated at refrigeration temperatures. Bacteriophage can
survive at high temperatures (40–90◦C) and some phages of Lac-
tococcus can survive pasteurization (Madera et al., 2004). In the
study of MS2 phage stability in different salt solutions the authors
showed that the monovalent salts did not inﬂuence phage titer
(Mylon et al., 2010). According to Langlet et al. (2008) higher
ionic strength can increase the aggregation of phage (Langlet et al.,
2008).
Besides these environmental conditions, the biochemical com-
position of the matrix also inﬂuences the accessibility of target
bacteria.
Accessibility to target bacteria
According to Marco et al. (2010) the diffusion of bacteriophages
could be impaired or favored depending on the structure and
the composition of the matrix and the environmental conditions
(Marco et al., 2010). In solidmedia, the diffusionof bacteriophages
could be limited, reducing phage adsorption on bacteria and, con-
sequently, the phage infection capacity. For example, Guenther
et al. (2009) have shown that the use of bacteriophages was lim-
ited by their diffusion in solid food matrices such as hot dogs,
smoked salmon and seafood.
The presence of other compounds could protect bacteria from
phages. The phage K is active on numerous strains of S. aureus,
but was inactive in raw milk which limits its application in bovine
mastitis (Gill et al., 2006a). O’Flaherty et al. (2005) suggested that
the immune factors present in raw milk prevented phages from
gaining access to bacteria. According to Gill et al. (2006b), some
proteins in whey may inhibit the adsorption of phage on bacteria.
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FIGURE 1 | Factors affecting the effectiveness of phage use against pathogenic bacteria.
In phage therapy, the escape of invasive pathogens into closed
tissue and organ compartments may block the effective use of
bacteriophages, especially if the phage cannot actively follow the
bacteria. It is also unclear how effective phages would be in treat-
ing diseases caused by intracellular pathogens (e.g., Salmonella
species), where bacteria multiply primarily inside human cells and
are inaccessible to phages (Sulakvelidze, 2005).
In the study of Chibani-Chennouﬁ et al. (2004) the author
showed that the survival of the bacteria in the gut during
the phage passage could only be explained by some physio-
logical reasons that prevented phage-induced lysis. The axenic
mice were infected with a single E. coli strain and then were
given phages in drinking water. The phage titers in the stools
increased in one day from the 105/mL in the drinking water
to 1010/ml in the stool while at the same time numbers of E.
coli in the stools reduced from 108 to 104 CFU/mL and stabi-
lized at 105 CFU/mL during the subsequent days. The bacteria
were not completely lysed in the stool although these bacteria are
sensitive to the phages. These results suggest that bacteria had
resided in gut sites protected from phage (Chibani-Chennouﬁ
et al., 2004).
Phages, unlike many antibiotic molecules, are not diffusible
across membranes and must therefore have a method of deliv-
ery to reach the target cells. Some researchers believe that the
best delivery mechanism may lie in using other non-pathogenic
species of bacteria to bring the phage to its pathogenic target
(Inal, 2003).
Circulation of phage and neutralization of phage by antibodies
To understand further the accessibility of phage to bacteria, some
authors have studied howphages circulate but few publications are
available on the subject. Some authors suggest that phages get into
the bloodstream of laboratory animals (after a single oral dose)
within 2 to 4 h and that they are found in the internal organs (liver,
spleen, kidney, etc.) in approximately 10 h. Also, data concerning
the persistence of administered phages indicate that phages can
remain in the human body for relatively prolonged periods of
time, i.e., up to several days (Bogovazova et al., 1991, 1992).
In an experimental design where mice were infected with the
φMR11 lysogen strain, no protection was observed allowing the
authors to conclude that a direct bactericidal effect of the phage
was the principal determinant of the protective effect rather than
any indirect effect such as a phage-stimulated immune response
(e.g., production of cytokines; Matsuzaki et al., 2003). Phage and
bacterial numbers in the circulation were determined after the
infection and showed that the bacterial load was much lower
in the blood of phage-treated mice when compared to those
that received only bacteria. They also noticed that phage titers
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in mice infected with bacteria remained higher than the titers
in mice that received only the phage. This suggested that the
phage had replicated in the infected mice and consumed the
bacteria.
Although the phage can circulate well in the blood and in dif-
ferent organs but some authors suggest that the phages may be
neutralized by antibodies which hamper phage effectiveness to
lyse the targeted bacteria. Geller et al. (1998) have showed that
the addition of colostrum in milk contaminated by phage pre-
vented the lysis of starter cultures of L. lactis. However, it is not
clear how long the antibodies will remain in circulation. Accord-
ing to (Sulakvelidze et al., 2001), the development of neutralizing
antibodies should not be a signiﬁcant obstacle during the initial
treatment of acute infections, because the kinetics of phage action
are much faster than the host’s production of neutralizing anti-
bodies. Moreover, if phage-neutralizing antibodies are still present
at the time the second course of treatment is administered or if
a rapid anamnestic immune response occurs before the phages
exert their action, it could be envisaged to repeat administration
or increase the phage concentration. Another solution to survive
the phage neutralization by antibodies would be to use different
phages because resistance is different from one phage to another.
Merril et al. (1996) developed an ingeniousmethod to solve this
problem. They succeeded in isolating the mutants, whose stability
in the blood increased, by repeating the following procedure eight
to ten times: (1) administrationof phages into the peritoneal cavity
of the mouse, (2) recovery of phages from the blood 7–18 h after
the injection, (3) multiplication of the recovered phages in vitro,
and (4) readministration of the proliferated phages to mice. The
mutant derived from phages after a long-circulating had capsid
protein modiﬁed (Merril et al., 1996).
Protection of phages
One of the solutions to protect the bacteriophage at the site of
infection and during the journey to this site is microencapsula-
tion which is deﬁned as a technology of packaging solids, liquids,
or gaseous materials in miniature capsules that can release their
contents at controlled rates under speciﬁc conditions. Microen-
capsulation has been applied to enhance the viability of probiotic
bacteria during processing and also for targeted delivery to the
gastrointestinal tract. The microencapsulation of viruses has been
studied as an effective adjuvant system to induce speciﬁc immune
responses via mucosal routes. Development of oral microencap-
sulated forms for bacteriophages to treat gastro infection in cattle
has been reported (Ma et al., 2008; Dini et al., 2012). These authors
have shown that the encapsulation technique enables a large pro-
portion of bacteriophage to remain bioactive in a simulated gas-
trointestinal tract environment, which indicates that these micro-
spheres may facilitate delivery of therapeutic phage to the gut.
Dose and moment of treatment
Another important factor that can modify the effectiveness of
phage treatment is single dose versus multiple doses. Several stud-
ies have shown that multiple doses are better than a single dose.
One study byHuff et al. (2003a,b) found that treating chickens suf-
fering from severe respiratory infections caused by E. coli was very
helpful in clearing up symptoms. The application of bacteriophage
was most useful very soon after the chickens had been exposed to
the bacteria and that, if treated early, multiple doses were better
than a single dose. Interestingly, if treatment starts later, there is
no difference between single or multiple doses, but treatment is
still very helpful (Huff et al., 2003a,b).
In a very thorough study, Biswas et al. (2002) performed experi-
ments using a mouse model of vancomycin- resistant Enterococcus
faecium infection. They showed ﬁrst that a phage administered
intraperitoneally 45 min post-infection was able to rescue mice
from E. faecium and that the rescue was associated with a sig-
niﬁcant decrease in bacterial numbers in the blood. They also
demonstrated that phage administration up to 5 h post-infection
still fully rescued the mice while treatment delayed beyond 5 h
rescued only some of the mice (Biswas et al., 2002).
Phage administration
One advantage of phage use is the easy administration. Phages
can be applied by oral, topical, intraperitoneal, intravenous, or
intranasal administration. The phage preparation and production
may be carried out in pathogenic bacterial culture. In this case
it must be controlling the toxin or the residues of bacteria cul-
ture which may provoke the inﬂammatory phenomenon (Gill and
Hyman, 2010).
Phage therapy has been used for the treatment of a variety of
bacterial infections. They can be used in freeze-dried form and
turned into pills without materially impacting efﬁciency. Temper-
ature stability up to 55◦C and shelf lives of 14 months have been
shown for some types of phages in pill form. Application in liquid
form is also possible, stored preferably in refrigerated vials.
Oral administration works better when an antacid is included,
as this increases the number of phages surviving passage through
the stomach.
Topical administration often involves application to gauzes that
are laid on the area to be treated.
In the study of efﬁcacy of bacteriophages for the treatment of
infections caused by Klebsiella ozaenae, K. rhinoscleromatis scle-
romatis and K. pneumonia (Bogovazova et al., 1991, 1992), the
phage preparation was reported to be efﬁcacious in treating exper-
imental infections of mice and guinea pigs. Klebsiella polyvalent
bacteriophage was administered intraperitoneally, intravenously
or intranasally on day 2 after the infection of the animals with
Klebsiella. The result showed that the bacteriophage introduced
intraperitoneally, was effective in the treatment of a generalized
Klebsiella infection. Other authors Chilamban et al. (2004) have
also shown that intravenous inoculation was faster than the intra-
mammary one when they studied the efﬁcacy of a speciﬁc lytic
phage against S. aureus in a mice model.
However, it is difﬁcult to conclude which mode of admin-
istration is the most effective. The effectiveness of treatment
depends on various factors: the concentration of pathogenic
bacteria on the infection site, phage preparation, and the dose
applied, medium composition and structure, and environmental
conditions...
Speciﬁcity
Phages speciﬁcally infect the host bacteria species. This speciﬁcity
can limit the effectiveness of phage use. To ensure that the bacteria
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canbe lysedby the phageused, the bacterial strain isolated from the
infection site will be tested for its sensitivity to the phage admin-
istrated. It is important also to verify if the phage is strongly lytic
or not. However, polyvalent phages which can infect several bac-
teria strains of the same species do exist. The use of polyvalent
phage allows the activity spectrum of phages to be increased. The
polyvalent phage can be replaced by a cocktail of phages. Brieﬂy,
the phage by their speciﬁcity can infect only the target bacteria
without effect on others bacteria ﬂora, but the speciﬁcity may also
have an ineffective treatment if the target bacteria are not lysed by
the phages administrated. To overcome the problem related to the
speciﬁcity of phage, several solutions are proposed:
- Isolating the bacteria from the infection site and screening the
sensitivity of this bacteria against a panel of bacteriophages.
- Selecting polyvalent bacteriophages with broad cross-strain lytic
activity
- Developing a cocktail of phages which could increase the spec-
trum of activity of the phages against all or most of the strains
within a given species of bacterial pathogen.
Resistance to phage
As in the case of antibiotics, bacteria can develop resistance to
phage, which may hamper the effectiveness of phage treatment.
The ﬁrst step of phage infection to bacteria is adhesion of phage
on bacterial surface by surface proteins which act as receptors.
If the bacterium loses the phage receptor, they become resistant
to phage. Bacteria may also acquire horizontally a restriction-
modiﬁcation system that degrades the nucleic acid of the injected
phage. In addition, phage resistance may be caused by a mutation
in a gene, the product of which is essential for phage replica-
tion or assembly. In any case, the resistance to phage does not
cause a problem for phage use or phage therapy because the rate
at which bacteria develop resistance to phages is approximately
10-fold lower than to antibiotics (Carlton, 1999). Moreover, this
rate can also be partially circumvented by using several phages in
one preparation much like using two or more antibiotics simul-
taneously. When resistance against a given phage occurs, a new
phage can be created to target and destroy the new strain. Some
protocols on isolation of phage have been mentioned in literature
(Garcia et al., 2009; Moineau and Fortier, 2009). The selection and
screening a new phage is faster than the development of novel
antibiotics which can take up to several years (Sulakvelidze et al.,
2001).
CONCLUSION
The use of bacteriophages as antimicrobial agents controlling
pathogenic bacteria has appeared as a promising new strategy and
it seems that phage therapy may provide a good alternative solu-
tion to antibiotics. The abundance of phages in the environment
highlights their potential use for control of pathogenic bacteria
in food and animals. For an effective treatment, bacteriophages
should be (1) present in high concentrations, (2) stable over time
and in in vivo conditions, (3) able to meet the bacteria without any
restriction, and (4) able to replicate. For that, some points should
be taken into account:
- Use a high level of phage concentration
- Use phage to treat the bacterial infection as soon as possible
- Test the stability of phage in real environmental conditions
- Protect the phage by microencapsulation
- Screen and develop the cocktail of phage lytic which is able to
infect many bacterial strains
- Use a polyvalent bacteriophages with broad cross-strain lytic
activity or develop aphage cocktail to lyse themajority of bacteria
strains and limit the development of resistance to phage
However, several challenges may arise in phage therapy such as:
- phages can be neutralized by antibodies or other components in
the matrices
- bacteria may develop on several sites which are inaccessible to
phage.
There is a need to develop a model which approaches the in
vivo conditions to elucidate the factor inﬂuence on the infection
capacity of phages before in vivo application.
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